Does In Vitro Cytochrome P450 Downregulation Translate to In Vivo Drug‐Drug Interactions? Preclinical and Clinical Studies With 13‐ cis ‐Retinoic Acid-Reference-Cited by-同舟云学术

Does In Vitro Cytochrome P450 Downregulation Translate to In Vivo Drug‐Drug Interactions? Preclinical and Clinical Studies With 13‐ cis ‐Retinoic Acid

Published:2019-03-20 Issue:4 Volume:12 Page:350-360
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Stevison Faith¹^ORCID,Kosaka Mika²,Kenny Jane R.²,Wong Susan²,Hogarth Cathryn³,Amory John K.⁴,Isoherranen Nina¹

Affiliation:

1. Department of PharmaceuticsSchool of PharmacyUniversity of Washington Seattle Washington USA

2. Department of Drug Metabolism and PharmacokineticsGenentech, Inc. South San Francisco California USA

3. The Center for Reproductive BiologySchool of Molecular BiosciencesWashington State University Pullman Washington USA

4. Department of MedicineUniversity of Washington Seattle Washington USA

Funder

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12616

Reference34 articles.

1. European Medicines Agency (EMA).Guideline on the investigation of drug interactions. 2012).

2. US Food and Drug Administration (FDA).Clinical Drug Interaction Studies – Study Design Data Analysis and Clinical Implications Guidance for Industry. (2017).

3. US Food and Drug Administration (FDA).In Vitro Metabolism‐ and Transporter‐Mediated Drug‐Drug Interaction Studies Guidance for Industry. (2017).

4. Intercept Pharmaceuticals Inc.OCALIVA (obeticholic acid) package insert. NDA number 207999. (2016).

5. Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic;Drug Metabolism Reviews;2024-07-26

2. LX-2 Stellate Cells Are a Model System for Investigating the Regulation of Hepatic Vitamin A Metabolism and Respond to Tumor Necrosis Factorαand Interleukin 1β;Drug Metabolism and Disposition;2024-03-14

3. Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4‐Conjugate), Based on an In Vitro–In Vivo Extrapolation Approach;Clinical Pharmacology & Therapeutics;2023-12-03

4. Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne;British Journal of Clinical Pharmacology;2023-11-21

5. CYP2D6 Activity Is Correlated with Changes in Plasma Concentrations of Taurocholic Acid during Pregnancy and Postpartum in CYP2D6 Extensive Metabolizers;Drug Metabolism and Disposition;2023-08-07